Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 30;106(5):e328-30.
doi: 10.17269/cjph.106.4926.

Prescribing medical cannabis in Canada: Are we being too cautious?

Stephanie Lake, Thomas Kerr, Julio Montaner  1
Affiliations

Prescribing medical cannabis in Canada: Are we being too cautious?

Stephanie Lake et al. Can J Public Health. .

Abstract
in English, French

There has been much recent discussion and debate surrounding cannabis in Canada, including the prescribing of medical cannabis for therapeutic purposes. Certain commentators - including the Canadian Medical Association (CMA) - have denounced the prescribing of cannabis for medical purposes due to a perceived lack of evidence related to the drug's efficacy, harms, and mechanism of action. In this commentary, we present arguments in favour of prescribing medical cannabis in Canada. We believe the anti-cannabis position taken by CMA and other commentators is not entirely evidence-based. Using the example of neuropathic pain, we present and summarize the clinical evidence surrounding smoked or vapourized cannabis, including recent evidence pertaining to the effectiveness of cannabis in comparison to existing standard pharmacotherapies for neuropathy. Further, we outline how the concerns expressed regarding cannabis' mechanism of action are inconsistent with current decision-making processes related to the prescribing of many common pharmaceuticals. Finally, we discuss potential secondary public health benefits of prescribing cannabis for pain-related disorders in Canada and North America.

Il y a eu récemment de nombreux débats et discussions sur le cannabis au Canada, notamment sur la prescription du cannabis médical à des fins thérapeutiques. Certains commentateurs–dont l’Association médicale canadienne (AMC)–dénoncent la prescription du cannabis à des fins médicales en raison du manque perçu de preuves de l’efficacité potentielle, des méfaits et du mécanisme d’action de cette drogue. Nous présentons ici les arguments en faveur de la prescription du cannabis médical au Canada. Nous croyons que la position anti-cannabis adoptée par l’AMC et par d’autres commentateurs n’est pas entièrement fondée sur les données probantes. En prenant l’exemple de la douleur neuropathique, nous présentons et nous résumons les preuves cliniques portant sur le cannabis fumé ou vaporisé, y compris les preuves récentes afférentes à l’efficacité du cannabis comparativement aux pharmacothérapies standard existantes contre les neuropathies. De plus, nous montrons que les préoccupations exprimées au sujet du mécanisme d’action du cannabis sont en contradiction avec les processus décisionnels actuels liés à la prescription de nombreux produits pharmaceutiques courants. Enfin, nous discutons des éventuels avantages secondaires pour la santé publique du fait de prescrire le cannabis pour les troubles liés à la douleur au Canada et en Amérique du Nord.

Keywords: Canada; Cannabis; medical marijuana; pain.

PubMed Disclaimer

References

    1. Janus A. Medical marijuana regime is ‘bad medicine,’ CMA head warns. 2014.
    1. California Medical Association. Physician Recommendations of Medical Cannabis: Guidelines of the Scientific Affairs Subcommittee on Medical Marijuana Practice Advisory. Sacramento, CA: California Medical Association; 2011.
    1. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med. 2009;122(10Suppl):S22–32. doi: 10.1016/j.amjmed.2009.04.007. - DOI - PubMed
    1. Abrams DI, Jay CD, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HI.-associated sensory neuropathy. Neurology. 2007;68:515–21. doi: 10.1212/01.wnl.0000253187.66183.9c. - DOI - PubMed
    1. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, et al. Smoked medicinal cannabis for neuropathic pain in HI.: A randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–80. doi: 10.1038/npp.2008.120. - DOI - PMC - PubMed

Substances

LinkOut - more resources